Coronavirus interactions in drug discovery - optimization and implementation

Description of the granted funding

Last November infections of a new kind of coronavirus were announced but no one could have then anticipated how large impact this new virus (SARS-CoV-2) would cause globally only few week after finding it. Now this SARS-CoV-2 has spread around almost every place on Earth including Finland. In this project a consortium of four groups from University of Helsinki and University of Eastern Finland plan to tackle the task in identifying molecules (drugs) that would interfere replication of the virus. Members of the consortia coverer different disciplines from virology to protein-protein interaction and structural biology ranging until drug discovery. We are planning to use a multiplicinary approach to test existing drugs that have already been allowed to be used in humans. We are testing which drugs or combination of drugs against human proteins would inhibit or slow down replication of the virus. This is the fastest way to get drugs against this virus.
Show more

Starting year

2020

End year

2022

Granted funding



Sarah Butcher Orcid -palvelun logo
321 237 €

Role in consortium of the Academy of Finland

Partner

Other consortium parties

Partner
University of Eastern Finland (336473)
260 494 €
Leader
University of Helsinki (336470)
404 291 €

Funder

Research Council of Finland

Funding instrument

Targeted Academy projects

Other information

Funding decision number

336471

Fields of science

Plant biology, microbiology, virology

Research fields

Mikrobiologia

Themes

Lisätalousarvio III 2020

Identified topics

covid, pandemic, vaccines